Clinical Trial Update: Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM [Phase 2, Phase 3]

View source ↗

Summary

Open-label extension study to assess the long-term safety and tolerability of aficamten in adults with hypertrophic cardiomyopathy. The trial is in Phase 2/3 an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertrophic Cardiomyopathy

Drugs mentioned

• Aficamten (aficamten)

Snippet

Sponsor: Cytokinetics | Conditions: Symptomatic Hypertrophic Cardiomyopathy (HCM) | Phase 2, Phase 3 | Status: ENROLLING_BY_INVITATION